Aberrant CpG methylation of theTFAP2Agene constitutes a mechanism for loss ofTFAP2Aexpression in human metastatic melanoma
Authors:
- Andrea R HallbergAHAndrea R Hallberg
- Sabine U VorrinkSVSabine U Vorrink
- Danielle R HudachekDHDanielle R Hudachek
- Kimberly Cramer-MoralesKCKimberly Cramer-Morales
- Mohammed M MilhemMohammed M Milhem
- Robert A CornellRCRobert A Cornell
- Frederick E DomannFDFrederick E Domann
- 2 December 2014
- journal article
- Published by Taylor & Francis in Epigenetics
- Vol. 9 (12) , 1641-1647
Abstract
Metastatic melanoma is a deadly treatment-resistant form of skin cancer whose global incidence is on the rise. During melanocyte transformation and melanoma progression the expression profile of many genes changes. Among these, a gene implicated in several steps of melanocyte development, TFAP2A, is frequently silenced; however, the molecular mechanism of TFAP2A silencing in human melanoma remains unknown. In this study, we measured TFAP2A mRNA expression in primary human melanocytes compared to 11 human melanoma samples by quantitative real-time RT-PCR. In addition, we assessed CpG DNA methylation of the TFAP2A promoter in these samples using bisulfite sequencing. Compared to primary melanocytes, which showed high TFAP2A mRNA expression and no promoter methylation, human melanoma samples showed decreased TFAP2A mRNA expression and increased promoter methylation. We further show that increased CpG methylation correlates with decreased TFAP2A mRNA expression. Using The Cancer Genome Atlas, we further identified TFAP2A as a gene displaying among the most decreased expression in stage 4 melanomas vs. non-stage 4 melanomas, and whose CpG methylation was frequently associated with lack of mRNA expression. Based on our data, we conclude that TFAP2A expression in human melanomas can be silenced by aberrant CpG methylation of the TFAP2A promoter. We have identified aberrant CpG DNA methylation as an epigenetic mark associated with TFAP2A silencing in human melanoma that could have significant implications for the therapy of human melanoma using epigenetic modifying drugs.Keywords
This publication has 21 references indexed in Scilit:
- Reversal of epigenetic silencing of AP-2alpha results in increased zinc uptake in DU-145 and LNCaP prostate cancer cellsCarcinogenesis, 2011
- Genotype–phenotype analysis of the branchio‐oculo‐facial syndromeAmerican Journal of Medical Genetics Part A, 2010
- PLX4032: does it keep its promise for metastatic melanoma treatment?Expert Opinion on Investigational Drugs, 2010
- Differentiation of Zebrafish Melanophores Depends on Transcription Factors AP2 Alpha and AP2 EpsilonPLOS Genetics, 2010
- CREB Inhibits AP-2α Expression to Regulate the Malignant Phenotype of MelanomaPLOS ONE, 2010
- Phase I Trial of Sequential Low-Dose 5-Aza-2′-Deoxycytidine Plus High-Dose Intravenous Bolus Interleukin-2 in Patients with Melanoma or Renal Cell CarcinomaClinical Cancer Research, 2006
- Hypermethylation of a Small CpGuanine-Rich Region Correlates with Loss of Activator Protein-2α Expression during Progression of Breast CancerCancer Research, 2004
- Transcription factor Ap-2α is necessary for development of embryonic melanophores, autonomic neurons and pharyngeal skeleton in zebrafishDevelopmental Biology, 2004
- Skeletal and pigment cell defects in the lockjaw mutant reveal multiple roles for zebrafish tfap2a in neural crest developmentDevelopmental Dynamics, 2003
- Loss of Activator Protein-2α Results in Overexpression of Protease-activated Receptor-1 and Correlates with the Malignant Phenotype of Human MelanomaJournal of Biological Chemistry, 2003